Neuroimmune multi-hit perspective of coronaviral infection

[1]  I. Cobos,et al.  Dysregulation of brain and choroid plexus cell types in severe COVID-19 , 2021, Nature.

[2]  O. Pansarasa,et al.  COVID‐19‐related neuropathology and microglial activation in elderly with and without dementia , 2021, Brain pathology.

[3]  J. Saez-Rodriguez,et al.  Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions , 2021, Immunity.

[4]  J. Peça,et al.  The old guard: Age-related changes in microglia and their consequences , 2021, Mechanisms of Ageing and Development.

[5]  B. Cohen,et al.  Brain cells derived from Alzheimer’s disease patients have multiple specific innate abnormalities in energy metabolism , 2021, Molecular Psychiatry.

[6]  S. Ferreira,et al.  Innate immune memory mediates increased susceptibility to Alzheimer’s disease-like pathology in sepsis surviving mice , 2021, Brain, Behavior, and Immunity.

[7]  C. Andrade,et al.  Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation? , 2021, Journal of Neuroimmune Pharmacology.

[8]  J. Lukens,et al.  Innate immunity at the crossroads of healthy brain maturation and neurodevelopmental disorders , 2021, Nature Reviews Immunology.

[9]  Thomas V. Wiecki,et al.  The default network of the human brain is associated with perceived social isolation , 2020, Nature Communications.

[10]  C. Conrad,et al.  Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 , 2020, Nature Neuroscience.

[11]  K. Stiasny,et al.  Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity , 2020, Frontiers in Medicine.

[12]  Peter B. Jones,et al.  Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment , 2020, Brain, Behavior, and Immunity.

[13]  R. Kean,et al.  Brain tissue-resident immune memory cells are required for long-term protection against CNS infection with rabies virus. , 2020, Future virology.

[14]  T. Lyngdoh,et al.  Deciphering the COVID‐19 cytokine storm: Systematic review and meta‐analysis , 2020, European journal of clinical investigation.

[15]  M. Lynch,et al.  Imposed mutational meltdown as an antiviral strategy , 2020, Evolution; international journal of organic evolution.

[16]  Madeline A. Lancaster,et al.  SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids , 2020, Cell Stem Cell.

[17]  M. Aepfelbacher,et al.  Neuropathology of patients with COVID-19 in Germany: a post-mortem case series , 2020, The Lancet Neurology.

[18]  D. Stellwagen,et al.  TNF-Mediated Homeostatic Synaptic Plasticity: From in vitro to in vivo Models , 2020, Frontiers in Cellular Neuroscience.

[19]  A. Tsatsakis,et al.  Unraveling the Possible Routes of SARS-COV-2 Invasion into the Central Nervous System , 2020, Current Treatment Options in Neurology.

[20]  O. Witte,et al.  Memory-Like Responses of Brain Microglia Are Controlled by Developmental State and Pathogen Dose , 2020, Frontiers in Immunology.

[21]  Chunlin Li,et al.  Coronavirus disease 2019 associated with aggressive neurological and mental abnormalities confirmed based on cerebrospinal fluid antibodies , 2020, Medicine.

[22]  Jay Gopalakrishnan,et al.  SARS‐CoV‐2 targets neurons of 3D human brain organoids , 2020, The EMBO journal.

[23]  M. Aarabi,et al.  Understanding the Immunologic Characteristics of Neurologic Manifestations of SARS-CoV-2 and Potential Immunological Mechanisms , 2020, Molecular Neurobiology.

[24]  W. Lukiw,et al.  SARS-CoV-2 Infectivity and Neurological Targets in the Brain , 2020, Cellular and Molecular Neurobiology.

[25]  A. Aguilar-Valles,et al.  Maternal Immune Activation and the Development of Dopaminergic Neurotransmission of the Offspring: Relevance for Schizophrenia and Other Psychoses , 2020, Frontiers in Psychiatry.

[26]  A. Sette,et al.  COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside , 2020, npj Parkinson's Disease.

[27]  R. Kuzniecky,et al.  Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports , 2020, Journal of Neuroinflammation.

[28]  J. Chan,et al.  SARS-CoV-2 infects human neural progenitor cells and brain organoids , 2020, Cell Research.

[29]  E. Hsiao,et al.  The Microbiome as a Modifier of Neurodegenerative Disease Risk. , 2020, Cell host & microbe.

[30]  J. Gomes,et al.  Neuropathogenesis of SARS-CoV-2 infection , 2020, eLife.

[31]  F. Benedetti,et al.  Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors , 2020, Brain, Behavior, and Immunity.

[32]  A. El Idrissi,et al.  Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients , 2020, Neurological Sciences.

[33]  L. Ferini-Strambi,et al.  COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable? , 2020, Journal of Neurology.

[34]  R. Thangavel,et al.  COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation , 2020, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[35]  V. Sharma,et al.  Impact of the COVID-19 pandemic on hyperacute stroke treatment: experience from a comprehensive stroke centre in Singapore , 2020, Journal of Thrombosis and Thrombolysis.

[36]  Pratik Sinha,et al.  Is a "Cytokine Storm" Relevant to COVID-19? , 2020, JAMA internal medicine.

[37]  S. Farhadian,et al.  Neuroinvasion of SARS-CoV-2 in human and mouse brain , 2020, bioRxiv.

[38]  D. Hermann,et al.  Stroke increases the expression of ACE2, the SARS-CoV-2 binding receptor, in murine lungs , 2020, Brain, Behavior, and Immunity.

[39]  J. Atkinson,et al.  The complement system in COVID-19: friend and foe? , 2020, JCI insight.

[40]  J. Isaacs,et al.  Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities , 2020, The Lancet Respiratory Medicine.

[41]  S. Otto,et al.  On the evolutionary epidemiology of SARS-CoV-2 , 2020, Current Biology.

[42]  Hedayat Sahraei,et al.  The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging” , 2020, Inflammation Research.

[43]  B. Lina,et al.  Systematic SARS-CoV-2 screening in cerebrospinal fluid during the COVID-19 pandemic , 2020, The Lancet Microbe.

[44]  M. Heneka,et al.  Immediate and long-term consequences of COVID-19 infections for the development of neurological disease , 2020, Alzheimer's Research & Therapy.

[45]  I. Nabipour,et al.  COVID-19 cytokine storm: The anger of inflammation , 2020, Cytokine.

[46]  M. Bostancıklıoğlu.  Temporal Correlation Between Neurological and Gastrointestinal Symptoms of SARS-CoV-2 , 2020, Inflammatory bowel diseases.

[47]  G. Gigli,et al.  Stroke in patients with SARS-CoV-2 infection: case series , 2020, Journal of Neurology.

[48]  A. Shahbazi,et al.  COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review , 2020, Journal of NeuroVirology.

[49]  D. Dhar,et al.  Gut microbiota and Covid-19- possible link and implications , 2020, Virus Research.

[50]  S. Mukherjee,et al.  In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs , 2020, Journal of medical virology.

[51]  M. Bostancıklıoğlu.  SARS-CoV2 entry and spread in the lymphatic drainage system of the brain , 2020, Brain, Behavior, and Immunity.

[52]  P. Calabresi,et al.  Does SARS‐Cov‐2 invade the brain? Translational lessons from animal models , 2020, European journal of neurology.

[53]  S. Kremer,et al.  Neurologic Features in Severe SARS-CoV-2 Infection , 2020, The New England journal of medicine.

[54]  Amber Dance.  What is a cytokine storm? , 2020 .

[55]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[56]  Xuetao Cao.  COVID-19: immunopathology and its implications for therapy , 2020, Nature Reviews Immunology.

[57]  L. French,et al.  The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains , 2020, bioRxiv.

[58]  F. A. Lagunas-Rangel.  Neutrophil‐to‐lymphocyte ratio and lymphocyte‐to‐C‐reactive protein ratio in patients with severe coronavirus disease 2019 (COVID‐19): A meta‐analysis , 2020, Journal of medical virology.

[59]  A. Cressant,et al.  Neuroinflammation and depression: A review , 2020, The European journal of neuroscience.

[60]  T. Fortin,et al.  Leucine-rich repeat kinase-2 (LRRK2) modulates microglial phenotype and dopaminergic neurodegeneration , 2020, Neurobiology of Aging.

[61]  J. Yakel,et al.  A novel role of NLRP3-generated IL-1β in the acute-chronic transition of peripheral lipopolysaccharide-elicited neuroinflammation: implications for sepsis-associated neurodegeneration , 2020, Journal of Neuroinflammation.

[62]  R. Zhou,et al.  DAMP-sensing receptors in sterile inflammation and inflammatory diseases , 2019, Nature Reviews Immunology.

[63]  Tiantian Han,et al.  Coronavirus infections and immune responses , 2020, Journal of medical virology.

[64]  M. Lynch,et al.  The role of the immune system in driving neuroinflammation , 2020, Brain and neuroscience advances.

[65]  R. Liu,et al.  Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors , 2020, Emerging microbes & infections.

[66]  G. Kassab,et al.  Cerebrovascular miRNAs correlate with the clearance of Aβ through perivascular route in younger 3xTg‐AD mice , 2020, Brain pathology.

[67]  D. Macdonald,et al.  Social effects on age-related and sex-specific immune cell profiles in a wild mammal , 2019, Biology Letters.

[68]  C. Ross,et al.  G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice. , 2019, Human molecular genetics.

[69]  Yan-song Liu,et al.  Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder , 2019, Brain, Behavior, and Immunity.

[70]  S. Chinnathambi,et al.  Microglial priming of antigen presentation and adaptive stimulation in Alzheimer’s disease , 2019, Cellular and Molecular Life Sciences.

[71]  Yong-Ku Kim,et al.  A review on inflammatory cytokine-induced alterations of the brain as potential neural biomarkers in post-traumatic stress disorder , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[72]  C. Cunningham,et al.  Priming Microglia for Innate Immune Memory in the Brain. , 2019, Trends in immunology.

[73]  I. Patro,et al.  Cumulative multiple early life hits- a potent threat leading to neurological disorders , 2019, Brain Research Bulletin.

[74]  V. Sossi,et al.  Single Inflammatory Trigger Leads to Neuroinflammation in LRRK2 Rodent Model without Degeneration of Dopaminergic Neurons. , 2019, Journal of Parkinson's disease.

[75]  J. L. Venero,et al.  Peripheral Inflammation Enhances Microglia Response and Nigral Dopaminergic Cell Death in an in vivo MPTP Model of Parkinson’s Disease , 2018, Front. Cell. Neurosci..

[76]  G. Shadel,et al.  Pink1/Parkin link inflammation, mitochondrial stress, and neurodegeneration , 2018, The Journal of cell biology.

[77]  J. Rini,et al.  Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43 , 2018, Journal of Virology.

[78]  T. Yamashita,et al.  The role of immune cells in brain development and neurodevelopmental diseases , 2018, International immunology.

[79]  D. Centonze,et al.  Tumor Necrosis Factor and Interleukin-1β Modulate Synaptic Plasticity during Neuroinflammation , 2018, Neural plasticity.

[80]  M. Staufenbiel,et al.  Innate immune memory in the brain shapes neurological disease hallmarks , 2018, Nature.

[81]  R. Duman,et al.  Depression and sterile inflammation: Essential role of danger associated molecular patterns , 2017, Brain, Behavior, and Immunity.

[82]  I. Amit,et al.  A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease , 2017, Cell.

[83]  C. Cotman,et al.  Cytokines and cytokine networks target neurons to modulate long-term potentiation. , 2017, Cytokine & growth factor reviews.

[84]  S. Nataf.  Evolution, immunity and the emergence of brain superautoantigens , 2017, F1000Research.

[85]  Seth L Masters,et al.  Inflammasome Priming in Sterile Inflammatory Disease. , 2017, Trends in molecular medicine.

[86]  S. Hayley,et al.  Individual and interactive sex-specific effects of acute restraint and systemic IFN-γ treatment on neurochemistry , 2017, Neurochemistry International.

[87]  Manoj Kumar,et al.  INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.

[88]  I. Martin,et al.  LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity , 2016, Journal of Chemical Neuroanatomy.

[89]  P. Lucassen,et al.  Microglial Priming and Alzheimer’s Disease: A Possible Role for (Early) Immune Challenges and Epigenetics? , 2016, Front. Hum. Neurosci..

[90]  S. Rivest,et al.  Microglia in Alzheimer’s disease: A multifaceted relationship , 2016, Brain, Behavior, and Immunity.

[91]  Zhiping Weng,et al.  Unexpected role of interferon-γ in regulating neuronal connectivity and social behavior , 2016, Nature.

[92]  V. Yong,et al.  Immunosenescence of microglia and macrophages: impact on the ageing central nervous system. , 2016, Brain : a journal of neurology.

[93]  G. Kollias,et al.  Neuroinflammatory TNFα Impairs Memory via Astrocyte Signaling , 2015, Cell.

[94]  S. Hayley,et al.  Paraquat and psychological stressor interactions as pertains to Parkinsonian co-morbidity , 2015, Neurobiology of Stress.

[95]  M. Campbell,et al.  The dynamic blood–brain barrier , 2015, The FEBS journal.

[96]  R. Yirmiya,et al.  Depression as a Microglial Disease , 2015, Trends in Neurosciences.

[97]  Huadong Zhou,et al.  The association between infectious burden and Parkinson's disease: A case-control study. , 2015, Parkinsonism & related disorders.

[98]  H. Kettenmann,et al.  Long-lasting pro-inflammatory suppression of microglia by LPS-preconditioning is mediated by RelB-dependent epigenetic silencing , 2015, Brain, Behavior, and Immunity.

[99]  W. V. van Gool,et al.  Systemic inflammation and microglial activation: systematic review of animal experiments , 2015, Journal of Neuroinflammation.

[100]  C. Pariante,et al.  Immune mechanisms linked to depression via oxidative stress and neuroprogression , 2015, Immunology.

[101]  R. Sankowski,et al.  Systemic Inflammation and the Brain: Novel Roles of Genetic, Molecular, and Environmental Cues as Drivers of Neurodegeneration , 2015, Front. Cell. Neurosci..

[102]  J. Blesa,et al.  Parkinson’s disease: animal models and dopaminergic cell vulnerability , 2014, Front. Neuroanat..

[103]  S. Hayley.  The neuroimmune-neuroplasticity interface and brain pathology , 2014, Front. Cell. Neurosci..

[104]  V. Perry,et al.  Microglial priming in neurodegenerative disease , 2014, Nature Reviews Neurology.

[105]  X. Chen,et al.  Rapid evolution of binding specificities and expression patterns of inhibitory CD33‐related Siglecs in primates , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[106]  F. Lotrich,et al.  Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications , 2013, Neuroscience.

[107]  L. Mestre,et al.  Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus , 2012, Progress in Neurobiology.

[108]  H. Anisman,et al.  Inflammatory Factors Contribute to Depression and Its Comorbid Conditions , 2012, Science Signaling.

[109]  S. Maier,et al.  Aging-related changes in neuroimmune-endocrine function: Implications for hippocampal-dependent cognition , 2012, Hormones and Behavior.

[110]  S. Hayley,et al.  Viral-toxin interactions and Parkinson’s disease: poly(I:C) priming enhanced the neurodegenerative effects of paraquat , 2012, Journal of Neuroinflammation.

[111]  Jesús Carretero,et al.  Leveraging social networks for understanding the evolution of epidemics , 2011, BMC Systems Biology.

[112]  H. Kettenmann,et al.  Physiology of microglia. , 2011, Physiological reviews.

[113]  S. Hayley,et al.  Inflammatory priming of the substantia nigra influences the impact of later paraquat exposure: Neuroimmune sensitization of neurodegeneration , 2009, Neurobiology of Aging.

[114]  P. Foley.  Encephalitis lethargica and the influenza virus. III. The influenza pandemic of 1918/19 and encephalitis lethargica: neuropathology and discussion , 2009, Journal of Neural Transmission.

[115]  T. Town,et al.  CNS Infiltration of Peripheral Immune Cells: D-Day for Neurodegenerative Disease? , 2009, Journal of Neuroimmune Pharmacology.

[116]  Y. Huang,et al.  Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1β and anti-inflammatory IL-10 cytokines , 2009, Brain, Behavior, and Immunity.

[117]  E. Hirsch,et al.  Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. , 2008, The Journal of clinical investigation.

[118]  H. Anisman,et al.  Lipopolysaccharide and a social stressor influence behaviour, corticosterone and cytokine levels: Divergent actions in cyclooxygenase-2 deficient mice and wild type controls , 2008, Journal of Neuroimmunology.

[119]  H. Anisman,et al.  Influence of poly I:C on sickness behaviors, plasma cytokines, corticosterone and central monoamine activity: Moderation by social stressors , 2007, Brain, Behavior, and Immunity.

[120]  R. Dantzer,et al.  Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide , 2007, Neurobiology of Aging.

[121]  A. McCormack,et al.  Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration , 2007, Neurobiology of Disease.

[122]  R. Malenka,et al.  Synaptic scaling mediated by glial TNF-α , 2006, Nature.

[123]  G. Almazan,et al.  Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice , 2006, Virology.

[124]  Jing Chen,et al.  Exaggerated neuroinflammation and sickness behavior in aged mice after activation of the peripheral innate immune system , 2005 .

[125]  H. Anisman,et al.  Neurochemical sensitization associated with systemic administration of tumor necrosis factor-α: adjuvant action in combination with bovine serum albumin , 2003, Journal of Neuroimmunology.

[126]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[127]  P. Talbot,et al.  Vacuolating encephalitis in mice infected by human coronavirus OC43 , 2003, Virology.

[128]  G. Aguilera,et al.  Single administration of interleukin-1 increased corticotropin releasing hormone and corticotropin releasing hormone-receptor mRNA in the hypothalamic paraventricular nucleus which paralleled long-lasting (weeks) sensitization to emotional stressors , 2003, Neuroscience.

[129]  S. Maier,et al.  Prior Stressor Exposure Sensitizes LPS-Induced Cytokine Production , 2002, Brain, Behavior, and Immunity.

[130]  H. Anisman,et al.  Central monoamine and plasma corticosterone changes induced by a bacterial endotoxin: sensitization and cross‐sensitization effects , 2001, The European journal of neuroscience.

[131]  C. Franceschi,et al.  Inflamm‐aging: An Evolutionary Perspective on Immunosenescence , 2000 .

[132]  H. Anisman,et al.  Synergistic Effects of Interleukin-1β, Interleukin-6, and Tumor Necrosis Factor-α: Central Monoamine, Corticosterone, and Behavioral Variations , 2000, Neuropsychopharmacology.

[133]  H. Anisman,et al.  Sensitization to the Effects of Tumor Necrosis Factor-α: Neuroendocrine, Central Monoamine, and Behavioral Variations , 1999, The Journal of Neuroscience.

[134]  H. Anisman,et al.  An assessment of the effects of central interleukin-1β, -2, -6, and tumor necrosis factor-α administration on some behavioural, neurochemical, endocrine and immune parameters in the rat , 1998, Neuroscience.

[135]  O. Garaschuk,et al.  Physiology of Microglia. , 2019, Methods in molecular biology.

[136]  J. Nikolich-Žugich.  The twilight of immunity: emerging concepts in aging of the immune system , 2017, Nature Immunology.

[137]  R. Malenka,et al.  Synaptic scaling mediated by glial TNF-alpha. , 2006, Nature.

[138]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[139]  H. Anisman,et al.  Synergistic effects of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha: central monoamine, corticosterone, and behavioral variations. , 2000, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[140]  A. Członkowska,et al.  MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. , 1999, Acta neurobiologiae experimentalis.